Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of SFX-01 in patients with chronic kidney disease (CKD).

Trial Profile

Clinical trial of SFX-01 in patients with chronic kidney disease (CKD).

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sulforafan (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions

Most Recent Events

  • 20 Feb 2020 New trial record
  • 13 Feb 2020 According to Evgen Pharma media release, Dr. Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center will lead the trial.With the assistance of Evgen, Professor Le will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval.
  • 13 Feb 2020 According to Evgen Pharma media release, the company and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top